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ABSTRACT
Mixed ligand oxo peroxo complexes ofvanadium (V), M[VO(O2)L2].nH20 where M K or NH4, HL
uracil or cytosine and n or 2, have been isolated from aqueous methanolic medium. The complexes were
characterised by elemental analysis, conductance, TGA, UV-Visible, !R and NMR spectral studies. Both the
peroxide and the other ligands acts as chelates coordinating through their oxygen at C (2) and nitrogen at N
(3) and the presence ofmonomeric oxoperoxovanadium (V) species, have been established by IR, H and 5V
NMR studies. The complexes appeared to possess pentagonal bipyramidal geometry. The terminal oxo ligand
and the oxygen of the uracil or cytosine at C (2) occupy the axial position while the peroxide and the other
donor ligands are in the equatorial position. The UV spectral studies confirm the presence of Vanadium in its
+5 oxidation state. The administration of the potassium salts of the complexes reduces the blood glucose
level in Swiss Albino mice compared to that of KVO3. The complexes also readily oxidise cysteine to cystine
in aqueous solution. The possible mechanism for the insulin- mimic activity ofthe complexes is discussed.
INTRODUCTION
The discovery of the insulin mimetic properties of vanadium (V) compounds has increased the
interest in the studies of the structure and reactivity of vanadium (V) complexes. The enhanced
insulin mimetic effect of the peroxo vanadium complexes has further increased the interest in the
coordination chemistry of vanadium24. The vanadium peroxo complexes are probably formed as
intermediates in oxidation reaction catalysed by vanadium bromo peroxidase, an enzyme from
marine algae5. Vanadium peroxo complexes have also been used in synthetic organic chemistry
since these compounds have potent and very desirable properties as catalysts6’7" As a result, the
studies on these vanadium peroxo complexes have appeared in several recent reviewss’9" The insulin
mimic property of vanadium (V) compound was first reported in 1980. Subsequently, it was
reported that mixtures of hydrogen peroxide and vanadates act as a more potent insulin mimetic
agent in controlling the blood glucose level in rats, than, either vanadates or hydrogen peroxidel’L
The mixtures of vanadates and hydrogen peroxide generate several peroxovanadium species
2 in
aqueous solution and the mixtures also become unstable losing their insulin mimetic activities with
2 2 time. Mixed ligand peroxo vanadium complexes have been isolated in solid state with pyridine-2-
earboxy.lic acid or with 1,10-phenanthroline as ligands, which exhibit, improved insulin mimetic
m3 activity Thus mixed ligand peroxo complexes of vanadium, containing N- and O-chelating donor
ligands act as potent insulin mimetic agents. A new insulin mimetic peroxo vanadium compound
containin imidazole
3 and naturally occuring chelating oxazolinate or thiazolinates has been
reported recently. Recent investigations of vanadium compounds as antidiabetic drugs in human
have enhanced the interest in both the chemistry and in the biological mechanism of actions of
vanadium5, 16. The nucleic acid bases such as uracil and cytosine possess the N- and O-donor
ligands. But there is no report on the mixed ligand peroxo complexes ofvanadium containing these
ligands though they themselves are of biological interest7,s. Both uracil and cytosine can undergo
tautomeric changes as shown in Fig. 1.
Hence, in continuation to our work on the interactions of the nucleic acid bases with metal
ions 9’2, we have undertaken the present investigation and report here the
isolation and characterisation of four novel mixed ligand peroxo vanadium complexes containing
uracil or cytosine as ligands. All the prepared complexes may be represented as
M[VO(O2)L2].nH20, whereM K or NH4, HL uracil or cytosine and n 1 or 2.
MATERIALS AND METHODS
Ammonium vanadate, uracil, cytosine were from Aldrich Chemical Company, USA.
Vanadium pentoxide was obtained from Sigma, USA. The other chemicals used were of analytical
grade. The uracil or cytosine is resistant to oxidation by H202 under the experimental conditions.
Preparation. ofthe Com..pt,lexes
KIVO(O2)(urahi.H20, (1): 0.91g (5.0 mrnol) of V205 dissolved in 0.65 g (11.6 mmol).of
KOH in 10 ml of water. A dear pale green solution was obtained. The solution was eooledo To this
solution previously cooled (5 C) 30 % H202 (1.5 ml, 13.2 mmol) was added and the resulting
solution became yellow. The mixture was cooled to 5 C. 2.5 g (22.3 mmol) of uracil (Hura)
dissolved in minimum volume ofaqueous methanol (50 %) was added to the above cooled mixture.
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The color of the resulting solution turned orange yellow. The pH of the solution was brought
around 7.5 by adding dropwise 0.1 (M) NaOH solution. The resulting solution was stirred for
hour and cooled to 5 C. A yellow precipitate was obtained that was recrystallised from 3 % H202
solution. (Yield: 1.6g, 42.1%). Anal Found: V, 13.87; C, 25.12; H, 2.52; N, 14.94 %. Calculated
for CsH8KNaOsV (F.W 378.1), V, 13.48; C, 25.39; H, 2.11; N, 14.81%.
O O H2 H2
Fig. 1: Tautomeric forms of uracil (a) and cytosine (b), and atoms numbering
KlVO(O)(cyt)l.HO (2): The yellow compound was obtained in the same way as adopted
for the above compound (1) except that 2.5 g (22.5 mmol) of cytosine (Hcyt) was used instead of
uracil. The yellow product was recrystallised from 3 % H_Oz solution. (Yield: 1.5 g, 39.9 %). Anal.
Found: V, 13.62; C, 25.26; H, 2.73; N, 22.59 %. Calculated for CsHIoKN606V (FW 376.1), V,
13.56; C, 25.53; H, 2.66; N, 22.33 %.
NH4lVO(O2)(urahl.2H20, (3): 0.59 g (5.0 mmol) of NH4VO3 was dissolved in 15 ml 6%
HzOz (26.4 mmol). The resulting solution, coloured yellow, was cooled to 5 C. To this 2.5 g (22.3
mmol) of uracil (Hura) dissolved in methanol was added. The colour of the resulting solution
became orange yellow. The pH of the solution was brought around 7.5 by adding 0.1 M NaOH
dropwise. The colour of the solution turns bright yellow. The solution was well stirred for lhour
and was kept at 5 C. Yellow precipitate was obtained which was recrystallysed from 3% HzOz
solution.(Yield: 0.6 g, 32%). Anal. Found: V, 13.68; C, 25.86; H, 3.97; N, 18.93. Calculated for
CsH14NsO9V (F.W 374.94), V, 13.59; C, 25.60; H, 3.73; N,18.67 %.
NH4lVO(O2)(eyth].21-1O (4): The compound was obtained in the same way as adopted for
the above compound (3) except that 2.5 g (22.5 mmol) of cytosine (Hcyt) was used instead ot
uracil, all other conditions remaining the same. The yellow compound was recrystallised from 3%
HzOz solution. (Yield: 0.5 g, 26.3%). Anal. Found: V, 13.74; C, 27.02; H, 4.40; N, 26.13 %.
Calculated for CsHI6N707V (FW, 373), V, 13.67; C, 26.74; H, 4.29; N, 26.27 %.
Analy..sis
Carbon, hydrogen and nitrogen microanalyses were obtained from the Indian Association for
the Cultivation of Science, Calcutta. Vanadium was estimated z by titration with a Fez+ solution in
the presence of sulphonated diphenylamine as indicator, after decomposing the sample with sodium
peroxide. The peroxo centent was determined by titration of a freshly prepared solution of the
compounds with potassium permanganate in 2 (N) sulphuric acid.
Physical Measurements
H NMR spectra of the potassium salts of the complexes were obtained in DzO at 19 C with a
JEOL FT-100 NMR spectrometer using HOD at 4.63 ppm as reference. The 5V NMR spectra of
the complexes were recorded in D_O with a Varian XL-300 NMR spectrometer using VOC13 as
external standard. The UV visible spectra were recorded either in a solid mull or in aqueous
solution using a DMR 21 Karl Zeiss spectrophotometer and the ir spectra were recorded in KBr
pellets by means of a 1330 Perkin-Elmer spectrophotometer. The conductivity measurements were
carried out with a PR 9500 Philips conductivity bridge. A thermogravimetric analysis was carried
out with a Derivatograph (system: F.Paulik, J. Paulik, L. Erday. MOM, Budapest). About 100 mg
ofthe finely powdered substances was heated at a rate of2 C per minute.
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Estimation ofblood glucose level
Blood glucose was estimated in Swiss Albino mice, weighing around 30 g each
speetrophotometrieally with ortho-toluidene as the reagent22. A calibration curve was recorded with
standard glucose solution of varying concentration from 25 to 200 tg L" containing 3%
triehloroaeetie acid and ortho-toluidene as the coloring agent. Blood glucose level was measured
from the calibration curve after treating the mice with vanadate solution, hydrogen peroxide and the
isolated potassium salts of the complexes with varying concentrations. The plasma blood glucose
contents of tile treated mice and the controlled untreated mice were calculated. The compounds in
aqueous solution were administered by a single intravenous tail vein injection of varying
concentrations ranging from 0.01 mmol to 0.06 mmol / kg wt in a volume of 1.5 I.tlg body weight.
Analysis ofplasma glucose levels ofblood was done by nicking the tip of the tail of the mouse and
collecting 5 tl blood into the injection syringe. The final volume was adjusted to 7.0 ml by adding
3% tdehloroaeetie acid solution. The solution was boiled for 10 minutes and then cooled to room
temperature for recording the absorbanee at 630 nm.
Oxidation ofeysteine tO .eystine
Stock solutions of L-eysteine lxl0" M, compounds solution 5x10
"2 M, potassium vanadate
5x10
2 M and H20 lxl0" M were prerared in phosphate buffer solution having pH 7.4. Solution of
eysteine and the compounds in the molar ratio 1"1, 2:1, and 4:1 were prepared by adding 10 ml
eysteine stock solution to the appropriate amount of oxidant, followed by dilution with buffer to 30
ml total volume. A control sample 10 ml of eysteine solution and 20 ml of buffer was prepared for
each experiment. All the reactions were carried out in nitrogen atmosphere and well stirred for 3
hours except those with KVO3 that was allowed to react for 20 hrs. Then the samples were filtered
through pre weighed sintered glass filters which were dried under vacuum overnight and reweighed
to give the yield of cystine. The cystine produced was identified in each case by comparing with its
HNMR spectra.
Fig. 2: Plasma blood glucose level on administration ofK[VO(O2)(ura)2].H20
at different concentrations and times
RESULTS
All the compounds are bright yellow in colour, non-hygroscopic and are stable at room
temperature. The compounds are soluble in water affording 10aM solution and the molar
2 conductance values lie in the range 108-125 ohm" cm mol indicating the presence of 1:1
electrolytes in aqueous solution. The thermograms of the ammonium salts of the complexes show
that they begin to decompose around 75 C and the decomposition takes place gradually without
the formation of any stable intermediates. Finally a horizontal is obtained around 450 C with a loss
ofaround 72 % indicating the total conversion of the sample into vanadium pentoxide.
I.R Data
The important ir absorption bands of the complexes are given in table I. All the compounds
show a very strong band around 940 cm which may be assigned due to O-O stretching of bidentate
peroxide group In addition to that another strong band around 620 cm
1 in all the compounds may
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be assigned due to assymetrie metal-peroxide vibrations. The absorption due to V=O vibration
around 970 cm
l indicate the high r-bond order of the vanadium-oxygen bond and also the presence
of monomeric oxovanadium species4. The absorption frequencies of the uracil complexes were
compared to that of the free uracil in the region between 1800 eml- 1300 ern
l where the CO and
NH frequency of uracil is located25. The bending vibrations ofN(1)-H at 1508 cm
1 of uracil in the
complex remains almost unchanged both in intensity and position while the vibration due to N(3)-H
of the uracil at 1417 em
l disappears completely in the complexes. The position and intensity of the
bands assignable to the 2-keto group at 1716 em
l of the uracil in the complexes change appreciably
with respect to free uracil while there is a little change for the vibrations of 4-keto group. So, in the
complexes uracil acts as a chelating ligand binding through its C(2)=O and N(3). The cytosine
complexes were also compared with that of the free cytosine as given in the literature6. The C-
NH+C-N ring stretching frequency at 1290 em
1 was split and shifted to higher frequency but with
reduced intensity. Since this shift is probably caused by the inductive and mesomerie effect of the
ring, N(3) site of the cytosine molecule in the complexes is assumed to be more positively charged
than the free cytosine molecule, indicating the coordination through N(3) of cytosine7.
Fig. 3: Plasma blood glucose level on administration of K[VO(O2)(cyt)2].H20
at different concentrations and times
The shoulder at 1660 cm
l and the strong band at 1503 cm
l in cytosine due to the C=N+C=C
stretching frequencies were shifted to higher frequencies in the complexes due to the redistribution
of r-electrons in the conjugated C=C, C=N and C=O systems of the cytosine ring. This also
supports the coordination of the metal through the N(3) of the cytosine32. The C=O band of
cytosine at 1650 cm-1 should shift to higher frequency on coordination because there is no longer
electron migration from the N(3) position to C(2). The almost unchanged position of the C=O band
both in position and intensity indicates the coordination also through C=O. Hence in these
complexes, cytosine also acts as a bidentate ligand coordinating through the nitrogen at N(3) and
the oxygen of C=O28. The bidentate peroxide ligand in general is bound in the equatorial plane
relative to the axial oxoligand in monomeric oxoperoxo vanadium complexes29. The oxygen donor
of another ligand molecule may serve as the seventh ligand as a long axial bond to possess
pentagonal bipyramidal geometry. In mono peroxo complexes the peroxide is symmetrically
coordinated.
UV Visible Spectra
The U.V visible spectra of the complexes show two bands. One low intensity band around 332
nm and one high intensity around 225 nm. Both the bands may be assigned due to-
d electron
rx h v n
30 transitions from the filled n* orbital of the pe o o group to toe aca t d orbital of vanadium The
high intensity peak around 225 nm will be due to the -r transitions of the uracil or cytosine
ligands and may also contain n-d and n*-d transition from the uracil or cytosine ligands to the
vacant d orbital of the vanadium31. The absence of d-d transitions in the visible region also
establishes the presence ofvanadium in its +5 state in the complex.
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Hura Hcyt
1716 s 1650 s
1660 sh
1675 s
1508
1417s
1503 s
Table I: Assignment of important IR bands (cm)
(1) (2) (3) (4)
1700 w 1640 s 1700 1645 s
1620 w 1625 w
1670 m, br 1670 m, br
1510m 1510m
1525 rn 1525 m
1290 rn 1300 vw 1300 vw
970 vs 975 vs 970 vs 975 vs
940 s 935 s 940 s 935 s
620 s 625 s 620 s 625 s
[Assignments
v[c(2)=o]
v[CN+CC]
v[C(4)=O+C=C]
5[N(1)-H]
v[CN+CC]
6[N(3)-H]
v[CNHE+CN]
v[V=O]
rio-o]
Vas[M-02]
Fig. 4: Plasma blood glucose level on administration ofKVO3 at different concentrations and times
NMR Spectra.
Selected H NMR signals of uracil, cytosine and the isolated vanadium peroxo complexes
containin those ligands are given in Table II. The assignments have been made as reported in the
literature ,33. The potassium complex containing the monodeprotonated uracil shows the presence
of N(1)-H groups (5=10.20 ppm ). On brining down the pH to around 4 by adding CF3COOH both
H(5) and H(6) signal shows a downfield shift from 5.71 ppm to 5.88 ppm and from 7.38 ppm to
7.44 ppm respectively. The greater downfield shift of the H(5) signal is explained by the
protonation of the oxygen at C(4) which is close to H(5) suggesting the presence of free oxygen at
C(4) and the co-ordination of the vanadium atom through O at C(2). The downfield shift of the
H(6) signal is explained by the protonation at the N(1) site. TheNMR spectra itself also indicate
the presence of free N(1)-H group. Hence, N(1) and oxygen at C(4) are not involved in bonding.
Table II. IH and 5VNMR signals of the ligand and the complexes (5, ppm)
Compound Solvent
H-C5( H-C6C6_) H-N(1)
Hura D20 5.53 (d) 7.49 (d) 10.12 (s)
(1) do- 5.71 (d) 7.38 (d) 10.20 (s)
-do- D20+CF3COOH 5.88 (d) 7.44 (d) 10.31 (s)
Hcyt D20 6.81 (d) 7.78 (d) 10.08 (s)
(2) do- 6.40 (d) 7.82 (d)
-do- D20+CF3COOH 6.44 (d) 7.92 (d)
1H
51v
-582
-588
This also supports our observation from the IR spectra that the uracilato anion co-ordinates to
vanadium through its O at C(2) and N at N(3). The complex containing the monodeprotonated
cytosine anion does not exhibit the signal for N(1)-H compared to that of free cytosine. Further on
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bringing down the pH around 4 by adding CF3COOH there is a further downfield shift of the C(5)-
H and C(6)-H signals. The downfield shift for C(6)-H (0.10 ppm) is higher compared to that for
C(5)-H (0.04 ppm). The greater downfield shift for C(6)-H can be explained due to the protonation
of the free N(1) site of the deprotonated cytosine anion in the complex. The 5V signal appeared at
-582 ppm and at -588 ppm for the above complexes is consistent with the monoperoxo species34.
BIOLOGICAL TESTS
Administration of our compounds (1), (2) and potassium vanadate over different concentration
and time reduces the plasma glucose level in the mice compared to the controlled mice as presented
in Fig. 2 and Fig. 3. The reduction is much more effective in the case of our compounds with
respect to potassium vanadate. The optimum dose of our compound is 003 mmol/kg wt for a period
of 2 hours which reduces the blood glucose level to 30 %. This reduction in blood glucose level is
slightly more than that observed for other vanadium peroxo complexes containing ligands having O
orN donor atoms35’36.
0 0
0
0
0 ,NH2 "-I"
o
(a) (b)
Fig. 5: Proposed structure pf the uracilato (a) and cytosinato (b) complexes
Oxidation of’ cystin,, to, Cystin
The reaction of the complex K[VO(O2)(ura)2].H20 and K[VO(O2)(cyt)2].H20 with cysteine
solution for 4 hours under nitrogen atmosphere with molar ratios of 1:1, 2:1, and 4:1 were carried
out. A fine white precipitate formed was collected and identified as cystine by its IH NMR
spectrum. This conversion to cystine was presented in Table III and compared to that observed for
KVO3 and H202. The reaction with H202 converts almost all cysteine to cystine. This observation
that the complexes (1) and (2) are much more efficient than potassium vanadate towards the
oxidation of cysteine to cystine is consistent with the greater insulin mimic activity.
Table.Ill: Conversion ofcysteine to cystine (%)
Molar ratio ComPOunds
Cysteine compound (1) (2) KVO3 H202
31 42 7.9 95
2" 52 48 27.5 95
4"1 43 44 6.8
DISCUSSION
The well characterised3s’36 insulin-mimetic oxoperoxopicolanatovanadium (V) dihydrate and
the anionic pyridine-2,6-dicarboxylatooxoperoxovanadate (V) monohydrate reduces the plasma
glucose level by 20 % in STZ-diabetic Sprague Dawley and insulin treated BB rats. In each case,
O- or N-donor atoms were bound to two or more sites in the vanadium (V) pentagonal bipyramidal
coordination sphere. The elemental analysis and conductance values supports the formulation of the
isolated complexes as K[VO(O2)(L2)].H20 and NH4[VO(O2)(L2)].2H20 where HL uracil or
cytosine. The peroxide and the uracil or cytosine ligand acts as chelates. The vanadium in the
complexes will assume pentagonal bipyramidal geometry. The peroxo group, the two nitrogen and
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one oxygen donor atoms of both ligands forms the equatorial plane. The remaining one oxygen
donor of the ligand and the oxygen of the oxo group are in the axial position (Fig. 5.)
The probable mechanism for the potent insulin mimic activity of the isolated potassium salts
of the complexes may be explained as follows. Insulin interacts with the extra cellular o-subunit of
the insulin rece,ltor that is attached to the plasma membrane by the -subunit, which passes through
the membrane’. The peroxovanadium complexes have been shown to be effective in stimulating
insulin receptor kinase (IRK) activity in hepatoma cells and inhibiting phosphotyrosine
phosphatase (PTPase) activity in rat liver endosomes3. A very. reactive cysteine residue at the
38 active site of PTPase forms a phosphate thioester intermediate during catalysis. The vanadate
anion oxidises cysteine to give cystine and esterifies the phenol group of N-acetyltyrosine
ethylester39. Hence, we have carried out the oxidation of cysteine with the isolated complexes. The
observation that the complexes are more efficient oxidising agents than the potassium vanadate at
the oxidative coupling of cysteine is consistent with the greater insulin mimic activity
4 of the
complexes.
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